Apple stock falls as foldable iPhone delay and China patent ruling

Apple’s shares dropped more than 4% in Tuesday trading, not because of weak earnings but due to worries about future growth prospects [1]. The market reacted to reports of engineering challenges delaying Apple’s first foldable iPhone and to a Chinese court ruling upholding rival AI patents that could increase Apple’s licensing costs [1].

Key takeaways

• Apple posted record iPhone revenue of $85.27 billion and total revenue of $143.76 billion, beating earnings expectations [1].
• A delay in the foldable iPhone, expected to represent less than 10% of this year’s lineup, is attributed to engineering hurdles rather than supplier issues [1].
• China’s Supreme People’s Court upheld AI patents held by Xiao‑I Corp, a setback that may raise Apple’s future licensing expenses in a key growth market [1].
• Analysts remain largely neutral to bullish, with UBS maintaining a $280 price target and Bank of America keeping a Buy rating with a $320 target [1].
• Apple’s market capitalization stands at about $4.5 trillion, making it the world’s third‑largest company by market value [3].

Engineering hurdles and legal setbacks dampen optimism

Apple’s latest earnings report showed a robust performance, with iPhone revenue reaching $85.27 billion and earnings per share of $2.84, surpassing the $2.67 consensus [1]. Nevertheless, investors are looking ahead to the company’s next hardware milestone. The anticipated foldable iPhone, projected to contribute less than 10% of this year’s product mix, is now facing engineering delays that could push its launch further out [1]. Prediction markets still assign a 77.5% chance of a launch before 2027, but the uncertainty has already weighed on the stock price.

At the same time, Apple is confronting a legal setback in China. On March 27, the Chinese Supreme People’s Court affirmed the validity of AI patents owned by Xiao‑I Corp, a decision that could force Apple into higher licensing costs in the Greater China market—a region that contributed $25.53 billion in the latest quarter, up 37.9% year over year [1]. The financial impact of the ruling remains unclear, but analysts note that it adds to broader regulatory risks in a key growth market.

Analyst outlook and market context

Despite the sell‑off, analyst sentiment has not turned sharply negative. UBS kept a neutral rating with a $280 price target, citing continued growth in the App Store and Services segments [1]. Bank of America maintained a Buy rating with a $320 target, pointing to upcoming product releases and AI integration as potential catalysts [1]. Overall, the average price target across analysts sits near $295, with 30 Buy, 16 Hold, and only 2 Sell recommendations [1].

Apple’s market cap of roughly $4.5 trillion underscores its scale, ranking it as the third‑largest public company worldwide [3]. The stock’s recent decline contrasts with its broader 12‑month gain of about 55%, reflecting the market’s confidence in Apple’s long‑term earnings power even as short‑term concerns emerge.

Why it matters

The combination of a delayed flagship product and a legal ruling in a major growth market highlights the risks that can outweigh strong quarterly results. Investors will watch how Apple resolves the foldable iPhone engineering issues and whether the China patent decision translates into higher operating costs. Continued analyst neutrality suggests that the market expects Apple’s core businesses—iPhone sales, Services revenue, and emerging AI initiatives—to sustain growth, but any further setbacks could pressure the stock more sharply.